Collage Photo of Guilherme Nader Marta and Ada Waks
Dec 11, 2024, 19:40
Guilherme Nader Marta: MARGOT trial results presented by Ada Waks at SABCS 2024
Guilherme Nader Marta, Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:
“MARGOT trial results presented by Ada Waks at SABCS 2024.
No statistically sig pCR benefit (56% vs 46%, p=0.25) between margetuximab vs. trastuzumab in combination with paclitaxel-pertuzumab in patients with HER2+ BC and CD16 genotype FF or FV.
Follow-up continues for EFS.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 15, 2025, 18:31
Jan 15, 2025, 18:25
Jan 15, 2025, 18:19
Jan 15, 2025, 17:48
Jan 15, 2025, 17:33
Jan 15, 2025, 17:27
Jan 15, 2025, 17:26
Jan 15, 2025, 17:19